Greenwich LifeSciences (GLSI) Share-based Compensation (2019 - 2026)

Greenwich LifeSciences (GLSI) has 7 years of Share-based Compensation data on file, last reported at $2.2 million in Q4 2025.

• Quarterly Share-based Compensation fell 60.31% year-over-year to $2.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.8 million (down 6.2% YoY) and the FY2025 annual result came in at $6.8 million, down 6.2% from the prior year.
• Share-based Compensation rose to $2.2 million in Q4 2025, from $1.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.5 million in Q4 2024 to a low of $165051.0 in Q1 2021.
• A 5-year average of $941959.4 and a median of $594522.0 in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation surged 820.03% — and 2025, when it tumbled 60.31%.
• Tracing GLSI's Share-based Compensation over 5 years: stood at $165429.0 in 2021, then surged by 259.38% to $594522.0 in 2022, then changed by 0.0% to $594522.0 in 2023, then surged by 820.03% to $5.5 million in 2024, then sank by 60.31% to $2.2 million in 2025.
• The last three Share-based Compensation figures came in at $2.2 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.